Nurr1 as a genetic target for treating levodopa-induced dyskinesias in Parkinson's disease

US10144932B2 · kind B2 · utility

Assignee

• BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY · US

Inventors

• Fredric Manfredsson · Grand Rapids, US
• Jack W. Lipton · Grand Rapids, US
• Nicholas Kanaan · Grand Rapids, US
• Timothy Collier · Rochester, US
• Kathy Steece-Collier · Grand Rapids, US
• Caryl E. Sortwell · Chicago, US

Key dates

• Filing date: Jun 5, 2015
• Grant date: Dec 4, 2018
• Expiry date: Jun 5, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2750/14143
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Methods of treating movement disorders by reducing the activity of Nurr1 are disclosed. These methods are particularly applicable to subjects suffering from Parkinson's disease who have either developed levodopa-induced dyskinesia (LID) or are at risk of developing LID. In some aspects, the invention relates to a method for treating a movement disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition, wherein said composition reduces the activity of a nuclea receptor related 1 protein (“Nurr1”). In some embodiments, the movement disorder is a dyskinesia. The movement disorder may be a levodopa-induced dyskinesia.